The University of New Mexico

Matthias Barton

Eric R Prossnitz

Matthias R Meyer

Geetanjali Sharma

The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity

The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

Growing community of inventors

Zurich, Switzerland

Matthias Barton